Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06338995 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT06338995 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 510 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06338995, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3650150
- DRUG Standard therapy for INCS
Study Locations (20)
California
- Keck Medicine of USC - Arcadia
- University of California, Irvine - Irvine
- DaVinci Research LLC - Roseville
- Breathe Clear Institute - Torrance
Florida
- Orlando ENT & Allergy - Orlando
- NuLine Clinical Trial Center - Pompano Beach
- University of South Florida - Tampa
Alabama
- AllerVie Clinical Research - Birmingham
- University of Alabama at Birmingham - Birmingham
Illinois
- Entopy Research LLC - Chicago
- Chicago ENT - Chicago
Missouri
- University of Missouri - Columbia
- Washington University School of Medicine - St Louis
Colorado
- Colorado ENT & Allergy - Colorado Springs
Idaho
- Treasure Valley Medical Research - Boise
Louisiana
- South Louisiana Ear, Nose, Throat & Facial Plastic Surgery - PPDS - Mandeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06338995
The ClinicalTrials.gov registry entry for NCT06338995 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06338995 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06338995 about?
NCT06338995 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)". The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
What is the current status of trial NCT06338995?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2024-04-29. Estimated completion is 2028-03.
What conditions does trial NCT06338995 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
What interventions are being tested in trial NCT06338995?
The interventions under investigation include: Placebo (DRUG), LY3650150 (DRUG), Standard therapy for INCS (DRUG).
Who is sponsoring clinical trial NCT06338995?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06338995 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.